Experimental cell therapy targets Hard-to-Treat tumors
NCT ID NCT07108140
First seen Jan 26, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This early-stage study tested a new treatment called ALPP CAR-T cells in 5 people with advanced solid tumors that had stopped responding to standard therapies. The goal was to see if the treatment was safe and to find the best dose. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Jinling Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.